Helping to advance biomanufacturing
At Teva, we’re investing over $500 million dollars to build a new, state-of-the-art biological manufacturing plant in Ulm Germany.
Automated with highly advanced manufacturing technology, this fast, efficient operation will not only allow us to
produce quality biosimilar medicines – it will allow us to do it at a price much lower than originator biologics.
